Seres (MCRB) Q2 Loss Narrows 34%
Seres Therapeutics (NASDAQ:MCRB), a clinical-stage biotech focused on microbiome therapeutics, released its second quarter 2025 earnings on August 6, 2025. The main highlight was a narrowing net loss from continuing operations (GAAP), driven by lower expenses and continued progress around its core asset, SER-155. The reported loss per share (GAAP) was $2.27, compared to an estimate of $2.49. No revenue was reported, as expected, following the sale of VOWST. The results point to a period of transition for the company, with financial discipline and an increased focus on clinical pipeline advancement characterizing the quarter. Management stated that existing cash resources are projected to fund operations into the first quarter of 2026, though further financing remains a critical need.
Source: Analyst estimates for the quarter provided by FactSet.
Seres is a biotechnology company aiming to discover and advance microbiome-based therapeutics. Its approach involves developing oral live biotherapeutics to repair or influence the human microbiome—communities of helpful bacteria in the gut—for disease treatment. Previously, it focused on commercializing VOWST, a microbiome capsule for C. difficile infection, with the majority of transition activities to Nestlé Health Science now complete.
Source Fool.com
